Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:111147 |
Name | angioimmunoblastic T-cell lymphoma |
Definition | A peripheral T-cell lymphoma characterized by autoimmune features and poor prognosis. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma T-cell non-Hodgkin lymphoma mature T-cell and NK-cell lymphoma peripheral T-cell lymphoma angioimmunoblastic T-cell lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TET2 mutant | N/A | angioimmunoblastic T-cell lymphoma | not applicable | detail... |
DNMT3A mutant | N/A | angioimmunoblastic T-cell lymphoma | not applicable | detail... |
IDH2 mutant | N/A | angioimmunoblastic T-cell lymphoma | not applicable | detail... |
IDH1 mutant | N/A | angioimmunoblastic T-cell lymphoma | not applicable | detail... |
TET2 T1063Nfs*5 TET2 E1207K | Dasatinib | angioimmunoblastic T-cell lymphoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02232516 | Phase II | Lenalidomide + Romidepsin | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT02689453 | Phase I | Alemtuzumab + rhIL-15 | Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) | Completed | USA | 0 |
NCT03017820 | Phase I | VSV-hIFNbeta-NIS | VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma | Recruiting | USA | 0 |
NCT03049449 | Phase I | Cyclophosphamide + Fludarabine 5F11-28Z CAR-T cells | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | Completed | USA | 0 |
NCT03081910 | Phase I | CD5 CAR-T cells Cyclophosphamide + Fludarabine | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) | Recruiting | USA | 0 |
NCT03372057 | Phase II | Duvelisib | A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) | Completed | USA | ITA | GBR | DEU | 0 |
NCT03586999 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Vincristine Sulfate | Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas | Completed | USA | 0 |
NCT03590574 | Phase Ib/II | AUTO4 | Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma | Active, not recruiting | GBR | ESP | 0 |
NCT03719105 | Phase I | Pembrolizumab Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Pralatrexate + Prednisone Calaspargase pegol-mknl + Dexamethasone + Etoposide + Ifosfamide + Methotrexate | Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | Recruiting | USA | 0 |
NCT03829540 | Phase I | CD4CAR | CD4CAR for CD4+ Leukemia and Lymphoma | Recruiting | USA | 0 |
NCT03900442 | Phase I | GGTI-2418 | Phase 1 Study of PTX-100 in Patients With Advanced Malignancies | Unknown status | AUS | 0 |
NCT03902184 | Phase II | Gemcitabine + Lacutamab + Oxaliplatin Lacutamab | IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK) | Active, not recruiting | USA | POL | ITA | FRA | ESP | DEU | BEL | AUT | 0 |
NCT04018248 | Phase I | BR101801 | BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) | Active, not recruiting | USA | 1 |
NCT04234048 | Phase I | Fenretinide | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04334174 | Phase II | Brentuximab vedotin | Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas (BRENTICON-T) | Withdrawn | USA | 0 |
NCT04569032 | Phase II | Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone | A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CZE | 0 |
NCT04639843 | Phase I | Azacitidine + Doxorubicin + Duvelisib + Romidepsin | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma | Withdrawn | USA | 0 |
NCT04703192 | Phase II | DS-3201b | Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 3 |
NCT04747236 | Phase II | Pralatrexate Belinostat Azacitidine + Romidepsin Gemcitabine Romidepsin | A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) | Recruiting | USA | 0 |
NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |
NCT04795869 | Phase II | Brentuximab vedotin + Pembrolizumab | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma | Withdrawn | USA | 0 |
NCT04803201 | Phase II | Cyclophosphamide + Doxorubicin + Duvelisib + Etoposide + Prednisone + Vincristine Sulfate Azacitidine + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Vincristine Sulfate | Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | Recruiting | USA | 0 |
NCT04984837 | Phase II | Gemcitabine + Oxaliplatin Gemcitabine + Lacutamab + Oxaliplatin | Study of Lacutamab in Peripheral T-cell Lymphoma | Recruiting | FRA | ESP | DEU | BEL | 0 |
NCT05006664 | Phase II | Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone | Brentuximab Vedotin in Combination With CHEP in Patient With PTCL | Unknown status | CZE | 0 |
NCT05010005 | Phase I | Duvelisib + Ruxolitinib | A Study of Ruxolitinib and Duvelisib in People With Lymphoma | Active, not recruiting | USA | 0 |
NCT05079282 | Phase I | ONO-4685 | Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | Recruiting | USA | 0 |
NCT05138458 | Phase Ib/II | Cyclophosphamide + Fludarabine + MT-101 MT-101 | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL (IMAGINE) | Suspended | USA | 0 |
NCT05274997 | Phase II | Linperlisib | A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma | Unknown status | USA | 0 |
NCT05371054 | Phase Ib/II | Prednisone + Venetoclax + VIP152 | Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies | Recruiting | USA | 0 |
NCT05377827 | Phase I | WU-CART-007 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT05883449 | Phase II | AB-101 + AFM13 Aldesleukin Cyclophosphamide + Fludarabine | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203) | Recruiting | USA | 0 |
NCT05967416 | Phase I | SIRPant-M | Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT05983965 | Phase I | Tazemetostat Acalabrutinib + Tazemetostat | Study of Tazemetostat in Lymphoid Malignancies | Recruiting | USA | 0 |
NCT06072131 | Phase III | Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate Cyclophosphamide + Pralatrexate + Prednisone + Vincristine Sulfate Belinostat + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate | To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL (CRESCENDO) | Recruiting | USA | POL | HUN | 2 |
NCT06393738 | Phase I | ARV-393 | A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | Recruiting | USA | ESP | DNK | CAN | 0 |
NCT06492304 | Phase Ib/II | CTX131 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | 0 |
NCT06561048 | Phase III | Pralatrexate CPI-818 Belinostat | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Recruiting | USA | 0 |
NCT06630091 | Phase II | Cyclophosphamide + Doxorubicin + Golidocitinib + Prednisone + Vincristine Sulfate | A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study | Not yet recruiting | USA | 0 |